Clinical Trials
27 trialsVorinostat and Temozolomide in Treating Patients With Malignant Gliomas
National Cancer Institute (NCI)
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
University of Nebraska
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
University of Nebraska
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Children's Oncology Group
G-FORCE-1
EpicentRx, Inc.
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
National Cancer Institute (NCI)
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
National Cancer Institute (NCI)
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
Duke University
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
National Cancer Institute (NCI)
Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma
National Cancer Institute (NCI)
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
National Cancer Institute (NCI)
Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic Glioma
Duke University
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
National Cancer Institute (NCI)
Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma
National Cancer Institute (NCI)
Imatinib Mesylate and Temozolomide in Treating Patients With Malignant Glioma
Duke University
PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas
Duke University
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
City of Hope Medical Center
Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors
National Institutes of Health Clinical Center (CC)
VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma
Northwestern University
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer
NYU Langone Health
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
City of Hope Medical Center
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Case Comprehensive Cancer Center